XMT-1592 is an ADC created using our proprietary Dolasynthen platform – a customizable and homogeneous platform designed to precisely optimize an ADC for a given target, drug-to-antibody ratio (DAR) and antibody. XMT-1592 comprises the same proprietary NaPi2b antibody and potent auristatin DolaLock payload with controlled bystander effect as upifitamab rilsodotin (UpRi), with the additional features of site-specific bioconjugation, precise DAR and homogeneous DAR distribution. In preclinical studies, Dolasynthen ADCs show enhanced pharmacokinetics, higher tumor exposure, and greater efficacy compared to Dolaflexin ADCs. We initiated a Phase 1 dose escalation trial of XMT-1592 in patients with tumors likely to express NaPi2b in May 2020.
For more information on this clinical trial, visit clinicaltrials.gov (NCT04396340).
Expanded Access Policy:
Expanded access, or compassionate use, is the use of an investigational medicine prior to regulatory approval and outside of a clinical trial. Mersana does not currently have an expanded access program or compassionate use program for any of our investigational products. We understand that for people living with cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trial programs is the best path to meet our goal of providing therapeutics to patients with cancer. We encourage any person with cancer interested in gaining access to our investigational therapies to consult with their physicians regarding the possibility of participating in one of our clinical trials.